Here are Top Health stories of the day
MBBS Abroad not advisable for lower, Middle-Class Indians, note NMC officials
New Delhi: MBBS abroad may not be a good option for lower and middle-class Indians, a recent paper penned down by the National Medical Commission (NMC) members has pointed out. The paper titled "Seeking graduation in medical colleges outside India: Is it a 'win–win situation or 'lose-lose situation' for the stakeholders and the nation? " written by the President of UG Medical Education Board of NMC, Dr. Aruna V Vanikar and three other members of the UGMEB has been published in The National Medical Journal of India.
"Seeking graduation in medical colleges outside India may not be advisable for those from the middle/ low-income group of India," the authors have noted in their article.
For more details, check out the full story on the link below:
MMCRI resident doctors go on strike over salaries, COVID-19 grant
Vacant MDS Seats: Health Ministry lowers cutoff by 23 percentile
In a major update for PG dental aspirants seeking admissions this academic year, it is hereby notified that the NEET MDS 2021 qualifying cut off has been lowered by 23.029 percentile for each category.
The qualifying percentile for the NEET MDS 2021 has been lowered from 50 to 26.971 for the general category bringing the score from 259 to 185 marks. For the SC/ST/OBC candidates, the qualifying percentile has been reduced from 40 to 16.971, hence the score goes down from 227 to 152; whereas for PwD (Persons with disabilities) category, the revised cut-off percentile is 21.971 down from 45, the score hence lowered from 243 to 170 marks.
For more details, check out the full story on the link given below:
Ahmednagar civil hospital staff start indefinite strike
Pharma firms seek Govt nod to hike drug prices by 20 percent
In view of the unprecedented crisis faced by Indian pharmaceutical firms due to the tremendous escalation of input costs, a lobby group that represents over 1,000 Indian pharmaceutical manufacturers has sought the government to allow drug makers to increase prices of all non-scheduled pharmaceuticals by 20 percent.
Non-scheduled medications are currently allowed a maximum annual price rise of 10%.